Wall Street brokerages expect Ventyx Biosciences Inc (NASDAQ:VTYX) to report earnings per share (EPS) of ($0.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Ventyx Biosciences’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.24). The business is scheduled to issue its next quarterly earnings report on Wednesday, February 16th.
On average, analysts expect that Ventyx Biosciences will report full-year earnings of ($3.66) per share for the current fiscal year, with EPS estimates ranging from ($5.46) to ($1.86). For the next financial year, analysts forecast that the firm will post earnings of ($1.59) per share, with EPS estimates ranging from ($2.18) to ($1.07). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Ventyx Biosciences.
A number of research firms recently commented on VTYX. Piper Sandler began coverage on shares of Ventyx Biosciences in a report on Monday, November 15th. They set an “overweight” rating and a $50.00 price target for the company. Evercore ISI began coverage on shares of Ventyx Biosciences in a report on Monday, November 15th. They set an “outperform” rating and a $50.00 price target for the company. Lifesci Capital reiterated an “outperform” rating on shares of Ventyx Biosciences in a report on Monday, November 15th. Finally, Jefferies Financial Group began coverage on shares of Ventyx Biosciences in a report on Monday, November 15th. They set a “buy” rating and a $30.00 price target for the company.
In related news, major shareholder Global Strategic Fund I. Venbio acquired 312,500 shares of the firm’s stock in a transaction on Monday, October 25th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company’s clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc is headquartered in Encinitas, California.
Further Reading: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.